Price (delayed)
$6.85
Market cap
$1.89B
P/E Ratio
85.63
Dividend/share
N/A
EPS
$0.08
Enterprise value
$2.31B
MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, its
There are no recent dividends present for MNKD.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.